** Shares of drugmaker Amgen AMGN.O down 1.74% at $284 premarket
** Co said U.S. FDA has placed a clinical hold on an early-stage trial of an experimental weight-loss drug, AMG 513
** The hold is to protect trial participants from unreasonable risk and to ensure that studies are conducted properly - AMGN
** Co added, discussions with regulators are ongoing to determine a path to reopen the study, and they do not believe the issue leading to the hold is drug-related
** AMGN posted a higher quarterly profit and said late-stage studies of another key obesity drug candidate, MariTide, will start before mid-year
** Obesity will continue to be a key theme for Amgen shares as we enter 2025 - Brokerage BMO Capital Markets
** Up to last close, stock down ~10% in last 12 months
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。